Angle PLC Announces Parsortix and Assays Being Showcased at EACR 2024
Angle PLC Announces Parsortix and Assays Being Showcased at EACR 2024
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH
PARSORTIX系统和试剂正在2024年欧洲抗癌研究协会年会上展示。
ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay
ANGLE发布两个海报,突出CTC和ctDNA双重分析的效用和ANGLE的DNA损伤反应测试。
GUILDFORD, SURREY / ACCESSWIRE / June 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024) being held in Rotterdam, Netherlands from 10 to 13 June 2024.
ANGLE plc(AIM:AGL)(OTCQX:ANPCY)是全球领先的液体活检公司,拥有创新的循环肿瘤细胞(CTC)解决方案,可用于研究、药物开发和临床肿瘤学。2024年6月10日至13日,在荷兰鹿特丹举行的2024年欧洲抗癌研究协会(EACR 2024)年会上展示。
ANGLE is presenting two posters at EACR 2024:
ANGLE在EACR 2024上发布了两张海报:
1. Targeted sequencing of circulating tumour cells captured by the Parsortix system enables low frequency variant analysis with pan-cancer Next Generation Sequencing (NGS) panel
1、通过Parsortix系统捕获的循环肿瘤细胞的靶向测序使得癌症病人的低频变异分析具备了全癌症下一代测序(NGS)板的能力。
The dual analysis of CTCs and circulating tumour DNA (ctDNA) is emerging as a workflow to provide a more comprehensive analysis of a patient's cancer*. In this presentation CTC-DNA obtained from Parsortix enriched CTCs and ctDNA from matched plasma samples from 10 ovarian, 13 breast, and 14 lung cancer patients were evaluated. Mutation profiles were reported using targeted NGS performed on the Illumina NextSeq 2000 platform.
CTC和循环肿瘤DNA(ctDNA)的双重分析正在成为提供病人癌症更全面分析的操作流程。在这个展示中,通过在Illumina NextSeq 2000平台上执行的靶向NGS分析CTC-DNA和来自10例卵巢癌、13例乳腺癌和14例肺癌病人甲型血浆样本中捕获的Parsortix富集的CTCs中的ctDNA。
In all three cancer types, higher percentages of mutations were identified exclusively in CTCs as compared to ctDNA. Mutations were co-detected in CTC and ctDNA at a frequency of 61%, 30% and 34% for samples from ovarian, breast and lung cancer patients respectively, demonstrating that both complementary and additional information can be obtained when investigating both sample types concurrently.
在这三种癌症类型中,CTC中独有的突变比ctDNA中的突变高。卵巢癌、乳腺癌和肺癌病人的样本中,CTC和ctDNA共同检测到的突变频率分别为61%、30%和34%,这表明同时检查两种样本类型可以获得互补和额外的信息。
This presentation highlights the value of profiling CTCs using the Parsortix system in addition to ctDNA analysis, to better report on genetic heterogeneity. The dual analysis of CTCs and ctDNA holds potential to guide personalised treatment selection and therapeutic monitoring towards improving the cancer patient care pathway.
这个展示突出了使用Parsortix系统对CTCs进行分析以及ctDNA分析的价值,可以更好地报告遗传异质性。CTC和ctDNA的双重分析有潜力用于指导个性化治疗选择和治疗监测,从而提高癌症患者的护理路径。
2. Detection of DNA damage in CTCs harvested from blood samples of ovarian and prostate cancer patients
2、检测从卵巢和前列腺癌患者的血液样本中收集到的CTCs中的DNA损伤。
Gamma H2AX (γ-H2AX) and Phospho KAP1 (pKAP1) are biomarkers used to identify the activation of the DNA damage response (DDR) pathway. Monitoring this activation can be important when evaluating the effectiveness of cancer therapies that target the DDR pathway. ANGLE has developed a DDR assay* for the assessment of these biomarkers in CTCs harvested using the Parsortix system.
Gamma H2AX(γ-H2AX)和Phospho KAP1(pKAP1)是用于识别DNA损伤反应(DDR)通路激活的生物标志物。在评估目标DDR通路的癌症治疗的有效性时,监测这种激活可能很重要。ANGLE已经开发了DDR测试用于评估使用Parsortix系统捕获的CTCs中的这些生物标志物。
This poster presentation reports on the performance of ANGLE's immunofluorescence assay for the identification of different CTC phenotypes (epithelial, mesenchymal and those transitioning) and the determination of DDR status (γ-H2AX or pKAP1). Analytical verification reported that the assay successfully produced linear data, with high analytical sensitivity1 and analytical specificity2 of ≥90% for epithelial, mesenchymal, blood lineage and DDR markers.
本展板报告了ANGLE用于识别不同CTC表型(上皮、间充质和转化)和确定DDR状态(γ-H2AX或pKAP1)的荧光免疫分析测试的性能。分析验证报告显示,该测试成功产生线性数据,并且具有良好的分析灵敏度和分析特异性1,对于上皮、间充质、血系和DDR标记而言,分析特异性≥90%。2对上皮细胞、间充质细胞、血液谱系和DDR标记物的检测准确率达到≥90%。
The presentation also reported that in samples from ovarian and prostate cancer patients, CTCs were found in 93% of patients overall; and in 62% of ovarian and 77% of prostate cancer patient samples one or more DDR positive CTCs were identified. This data demonstrates the feasibility of using the Parsortix system in combination with ANGLE's DDR assay to monitor CTC count and DDR status as a method of real-time treatment assessment.
本展示还报告了,在卵巢和前列腺癌患者的样本中,CTCs在整体病人中被发现了93%;在卵巢癌和前列腺癌患者样本中,62%和77%的样本中至少有一个DDR阳性的CTC被鉴定出来。这些数据说明了使用Parsortix系统与ANGLE的DDR测试结合监测CTC数和DDR状态作为实时治疗评估方法的可行性。
ANGLE Chief Scientific Officer, Karen Miller, commented:
ANGLE首席科学家Karen Miller评论说:
"We are delighted to have had two posters presented at the EACR 2024. The results of these studies further demonstrate the utility of ANGLE's technology for dual analysis of CTC-DNA and ctDNA and the utility of ANGLE's DDR assay. These solutions are at the forefront of cancer research, and we look forward to discussions with translational researchers and industry partners at this event."
“我们很高兴两张海报出现在EACR2024年会上。这些研究结果进一步证明了ANGLE技术的双重分析CTC-DNA和ctDNA的实用性以及ANGLE的DDR测试的实用性。这些解决方案位于癌症研究的最前沿,我们期待在本次活动中与转化研究人员和行业伙伴进行讨论。”
For further information:
进一步了解:
ANGLE plc |
+44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
Berenberg (NOMAD and Broker) |
|
FTI Consulting |
|
ANGLE plc |
+44(0)1483 343434 |
Andrew Newland,首席执行官 |
|
Berenberg(NOMAD和经纪人) |
|
fti咨询 |
|
*For Research Use Only. Not for use in diagnostic procedures.
研究用途。不用于诊断程序。
1. Analytical sensitivity = proportion of harvested cells known to express the marker(s) of interest which were marker positive in the assay.
1. 分析灵敏度=在采收的细胞中,已知表达感兴趣标记物的细胞比例,在这些细胞中,标记是阳性的比例。
2. Analytical specificity = proportion of harvested cells known to NOT express the marker(s) of interest which were marker negative in the assay.
2. 分析特异性=在采收的细胞中,已知不表达感兴趣标记物的细胞比例,在这些细胞中,标记是阴性的比例。
For Frequently Used Terms, please see the Company's website on
有关常用术语,请参阅该公司网站,网址为
Notes for editors
编辑注释
About ANGLE plc
关于ANGLE Plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE是一家领先的液体活检公司,为研究、药物开发和临床肿瘤学提供创新的循环肿瘤细胞(CTC)解决方案,可以使用简单的血液样本。 ANGLE的FDA批准和受保护的循环肿瘤细胞(CTC)收获技术称为Parsortix PC1系统,使得对样本的完整下游分析包括整个细胞成像和蛋白组分析以及全基因组和转录组分子分析成为可能。ANGLE的商业业务专注于诊断产品和临床服务。 诊断产品包括Parsortix系统和相关消耗品。 通过ANGLE在英国的符合GCP的实验室提供临床服务业务。 这些服务包括为制药业定制的测定开发和临床试验测试。 Parsortix系统的超过90篇同行评议的出版物证明了其表现。 欲了解更多信息,请访问
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.
Parsortix系统ANGLE的GCP合规实验室通过提供实验室和临床试验测试提供临床服务业务。这些服务包括为制药业定制的测定开发和临床试验测试。
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit
超过90篇同行评议的出版物证明了Parsortix系统的性能。 欲了解更多信息,请访问
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit .
此信息由伦敦证券交易所的新闻发布非监管分发服务Reach提供。可能适用于使用和分发此信息的条款和条件。如需更多信息,请联系rns@lseg.com或访问。
SOURCE: ANGLE plc
来源:ANGLE plc